1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
RegenETP, Inc.

RegenETP, Inc.

RGTPQ
RegenETP, Inc.US flagOther OTC
0.16
USD
- -
- -
1.18MMarket Cap
RegenETP, Inc.
RGTPQ
(Other OTC)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
2,239.91
2,435.18
3,331.41
2,145.68
3,414.67
3,474.93
1,193.01
802.9
136.23
- -
- -
2.56
5.66
6.53
2.94
0.12
0.01
Revenue per Share
-209.63
127.77
-253.56
-27.57
186.2
121.17
-319.08
-378.39
-123.36
-126.93
-666.84
-121.5
-92.62
-27.63
-9.43
-1.14
-1.27
Basic EPS, GAAP
-40.83
-114.81
-237.16
-94.11
243.98
151.15
-122.69
-90.08
-32.85
-21.06
-51.42
-61.87
-59.5
-25.2
-7.11
-3.3
-3.3
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
119.27
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-4,284.74
-3,588.41
-3,573.75
-2,901.46
-2,601.66
-2,386.35
-2,612.9
-2,796.87
-2,514.38
-1,528.78
-1,315.16
-531.51
-435.92
-308.25
-158.85
-75.33
-79.32
Book Value per Share
89.74
272.04
413.34
340.59
633.24
770.63
506.13
129.68
101.02
-56.73
-557.68
131.76
37.96
17.1
6.01
2.42
1.89
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
3
7
7
Basic Weighted Avg Shares
51
64
94
76
125
132
47
34
7
- -
- -
2
6
10
9
1
- -
Sales/Revenue/Turnover
-7.51
1.89
-5.51
-2.25
10.27
3.73
-22.82
-37.85
-46.11
- -
- -
-4,442.23
-1,652.39
-415.82
-344.3
-3,178.99
-29,868.49
Operating Margin (%)
3
6
14
7
7
18
7
11
- -
- -
- -
1
3
3
3
2
1
Depreciation Expense
-5
3
-7
-1
7
5
-13
-16
-4
-5
-131
-65
-92
-43
-30
-8
-8
Net Income, GAAP
- -
0.77
- -
- -
5.87
1.56
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-9.36
5.25
-7.61
-1.28
5.45
3.49
-26.75
-47.13
-56.91
- -
- -
-4,186.88
-1,636.46
-423.21
-321
-962.29
-11,376.71
Profit Margin (%)
3
7
12
12
24
28
16
5
16
5
3
68
22
23
18
11
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
4
3
- -
3
2
LT Debt
3
7
12
12
23
29
20
6
16
5
5
82
39
27
19
17
12
Total Equity
- -
24.58
- -
- -
67.94
18.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-4.17
- -
- -
-8.1
-5.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
5
3
3

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
18
13
9
Cash, Cash Equivalents & STI
16
11
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
2
2
Payables & Accruals
2
1
2
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
150.79%
301.61%
-13.65%
Free Cash Flow
47.33%
50.75%
-0.52%
Net Income, GAAP
215.31%
-33.18%
-74.05%
Sales/Revenue/Turnover
- -
33.13%
-91.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
5
3
1
1
9
2022
1
- -
- -
- -
1
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-5.72
-0.99
-0.31
- -
-9.43
2022
-1.12
-0.01
-0.47
- -
-1.14
2023
-0.58
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Diamyd Medical AB (publ) (DMYD-B.ST)
Clarus Therapeutics Holdings, Inc. (CRXWQ)
NewAmsterdam Pharma Company N.V. (NAMS)
HCW Biologics Inc. (HCWB)
Kezar Life Sciences, Inc. (KZR)
NuCana plc (NCNA)
Business
RegenETP, Inc. (RGTPQ) operates as a clinical-stage biotechnology company focused on developing and commercializing regenerative tissue products and biomaterials for medicine, biomedical engineering, and material sciences, primarily in the United States; core offerings include SkinTE, an autologous heterogeneous skin construct used for repairing, reconstructing, replacing, and supplementing skin in patients with acute or chronic wounds, burns, surgical reconstruction events, scar revision, or dysfunctional skin grafts; SkinTE Cryo, enabling multiple deployments from a single harvest via cryopreservation; a SkinTE point-of-care processing device; and contract research services, with operations conducted through Regenerative Medicine Products and Contract Services segments. Founded as PolarityTE, Inc. and headquartered at 1960 South 4250 West, Salt Lake City, Utah, the company changed its name to RegenETP, Inc. in August 2023 amid financial restructuring, including a Chapter 11 bankruptcy filing; in May 2024, it secured $12.5 million in funding from institutional investors and shareholders plus a $5.0 million senior secured credit facility from Avenue Venture Opportunities Fund, L.P.; earlier in August 2023, substantially all assets—including SkinTE and its FDA investigational new drug application—were acquired by Grander Acquisition LLC (operating as private PolarityTE or PolarityBio), which continues advancing pivotal studies for a biologics license application targeting chronic cutaneous ulcers such as diabetic foot ulcers, with ongoing publications supporting efficacy in Wagner 1 diabetic foot ulcers, pressure injuries, and traumatic wounds.